%0 Journal Article
%T Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting
%A Patrick Langford
%A Paul Chrisp
%J Core Evidence
%D 2010
%I 
%R http://dx.doi.org/10.2147/CE.S6012
%X saprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting Review (3641) Total Article Views Authors: Patrick Langford, Paul Chrisp Published Date September 2010 Volume 2010:5 Pages 77 - 90 DOI: http://dx.doi.org/10.2147/CE.S6012 Patrick Langford1, Paul Chrisp2 1Prime Medica Ltd, Knutsford, UK; 2Core Medical Publishing, Knutsford, UK; These affiliations were correct at the time the manuscript was prepared Introduction: The selective neurokinin-1 receptor antagonist aprepitant is effective in the treatment of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with both moderately and highly emetogenic chemotherapy. Fosaprepitant has been developed as an intravenous prodrug of aprepitant. Aims: To update the evidence underlying the use of fosaprepitant to prevent CINV. Evidence review: Aprepitant in combination with a serotonin antagonist and a corticosteroid controls acute and delayed symptoms of CINV in patients receiving moderately to highly emetogenic chemotherapy. Bioequivalence of fosaprepitant with aprepitant has recently been demonstrated, which has led to its inclusion in clinical guidelines for treatment of acute CINV with highly, and some regimens of moderately, emetogenic chemotherapy. Early studies of the clinical efficacy of fosaprepitant have shown improvement over treatment with ondansetron. Both aprepitant and fosaprepitant are well tolerated with most adverse events observed of mild or moderate intensity. Conflicting economic evidence has shown that whilst aprepitant provides an increased quality of life in patients treated for CINV, there are differing views over its absolute cost in relation to standard therapy. The incremental cost-effectiveness ratio of aprepitant, however, appears to lie within acceptable bounds. Place in therapy: Fosaprepitant and aprepitant are recommended in guidelines for preventing CINV due to moderately and highly emetogenic chemotherapy. Fosaprepitant is bioequivalent to aprepitant, and could offer potential benefits for patients who may be unable to tolerate oral administration of antiemetics during an episode of nausea or vomiting.
%K fosaprepitant
%K aprepitant
%K chemotherapy
%K nausea
%K vomiting
%U https://www.dovepress.com/fosaprepitant-and-aprepitant-an-update-of-the-evidence-for-their-place-peer-reviewed-article-CE